Overview

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines

Status:
Not yet recruiting
Trial end date:
2024-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of remibrutinib (LOU064) in adult Japanese chronic spontaneous urticaria (CSU) participants inadequately controlled by second generation H1-antihistamines.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals